AstraZeneca’s Huge $39-Billion Alexion Acquisition Results In Fall In Its Shares
The announcement of the $39 billion deal for acquisition of the United States based biotech company Alexion Pharmaceuticals by the British pharma company AstraZeneca resulted in a drop of 9 per cent in the share price of the British drug maker. According ot analysts, investors were spooked by the costs for the company because of…








